Latest Bellus Health Inc (BLUSF) Headlines
Escherichia Coli Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cr359v/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2013" report to their offering. 'Escherichia Coli Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Scope - A snapshot of the global therapeutic scenario for Escherichia Coli Infections. - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Escherichia Coli Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Rib-X Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. BELLUS Health Inc NovaBay Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Achaogen Inc. Evolva SA GlycoVaxyn AG Pt. Bio Farma Zymenex A/S Sequoia Sciences, Inc. Cellceutix Corporation TheraCarb Inc. Phico Therapeutics Ltd. AvidBiotics Corp. Trana Discovery, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/cr...ichia_coli About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alzheon Launches with Veteran Team and Funding to Accelerate Drug Development in Alzheimer's Disease and Other Neurodegenerative Disorders
Business Wire - Wed Oct 23, 5:00AM CDT
--Company to Advance ALZ-801 into Phase 2 Clinical Study in Patients with Alzheimer's Disease
Thallion Pharmaceuticals Announces Cash Component of $0.1889 Per Share
Marketwire - Fri Aug 09, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a notice to BELLUS Health indicating that Thallion has negotiated a final and binding agreement with Iberville Development Leasing Limited pursuant to which the latter has agreed to fully, finally and irrevocably release Thallion from its obligations under the lease dated December 2, 2010, in exchange for the payment of an amount which is less than the provision for the termination of such lease included in the minimum net cash component announced on August 2, 2013. The cash component of the consideration payable on the effectiveness of the Arrangement has been increased by $0.0124 per common share resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being $0.1889 per common share.
Thallion Announces Shareholder Approval for Plan of Arrangement and Date and Time for the Motion for Final Court Order
Marketwire - Tue Aug 06, 4:00PM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that the shareholders of Thallion approved the previously announced plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health at the annual and special meeting of the shareholders held today in Montreal (the "Meeting"). Pursuant to the Arrangement, the Shareholders will receive cash consideration of at least $0.1765 per common share, and one contingent value right ("CVR") per common share, entitling the holder thereof to: (A) its pro rata share of 100% of any additional purchase price consideration to be received from Premium Brands Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), (B) its pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS Health, capped at $6.5 million (or $0.1812 per CVR), and Copyright its pro rata share of 100% of any net proceeds generated from the licensing, selling or otherwise commercializing of (i) diagnostic products or services using certain Caprion Proteomics Inc. products, and (ii) all issued patents or pending patents pertaining to such Caprion Proteomics Inc. products, in respect of which Thallion has an ownership interest or monetary entitlement.
RETRANSMISSION/Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 9:54AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component").
Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component").
Thallion Announces 2013 Second Quarter Operating Results
Marketwire - Thu Jul 25, 4:01PM CDT
Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) today announced its operational and financial results for the 2013 second quarter ended May 31, 2013.
RETRANSMISSION: BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Fri Jul 12, 4:25PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") and Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment") to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health.
BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Wed Jul 10, 6:01AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") and Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment") to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health.
Thallion's Annual and Special Meeting to Be Held August 6, 2013
Marketwire - Tue Jul 02, 2:10PM CDT
Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) ("Thallion") announced today that the Superior Court of Quebec has issued an interim order authorizing Thallion to hold an annual and special meeting of the shareholders of Thallion, at which shareholders will be asked to approve the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health Inc. ("BELLUS Health") (TSX: BLU), which was announced previously on June 18, 2013.
Jaguar Recommends Disclosure of Net Cash Calculation
Filing Services Canada - Wed Jun 26, 2:20PM CDT
Jaguar Financial Corporation,("Jaguar") (TSX: JFC) today recommended that Thallion Pharmaceuticals Inc. ("Thallion" or the "Company") disclose the May 31, 2013 Net Cash calculation which was omitted in the Acquisition Agreement with BELLUS Health Inc. ("BELLUS") filed on SEDAR.
Thallion Reaffirms Support of BELLUS Health Acquisition
Marketwire Canada - Thu Jun 20, 6:30AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE:TLN) announced today that, in response to the press release dated June 18, 2013 issued by Jaguar Financial Corporation ("Jaguar"), it reaffirms its support of the BELLUS Health Inc. ("BELLUS") (TSX:BLU) proposed transaction outlined in Thallion's and BELLUS' joint press release dated June 18, 2013.
Escherichia Coli Infections - Pipeline Review, H2 2013
M2 - Wed Nov 06, 2:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cr359v/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2013" report to their offering. 'Escherichia Coli Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Scope - A snapshot of the global therapeutic scenario for Escherichia Coli Infections. - A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Escherichia Coli Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genentech, Inc. Rib-X Pharmaceuticals, Inc. Affinium Pharmaceuticals, Inc. BELLUS Health Inc NovaBay Pharmaceuticals, Inc. Nymox Pharmaceutical Corporation Achaogen Inc. Evolva SA GlycoVaxyn AG Pt. Bio Farma Zymenex A/S Sequoia Sciences, Inc. Cellceutix Corporation TheraCarb Inc. Phico Therapeutics Ltd. AvidBiotics Corp. Trana Discovery, Inc. Cantab Biopharmaceuticals Limited For more information visit http://www.researchandmarkets.com/research/cr...ichia_coli About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alzheon Launches with Veteran Team and Funding to Accelerate Drug Development in Alzheimer's Disease and Other Neurodegenerative Disorders
Business Wire - Wed Oct 23, 5:00AM CDT
--Company to Advance ALZ-801 into Phase 2 Clinical Study in Patients with Alzheimer's Disease
Thallion Pharmaceuticals Announces Cash Component of $0.1889 Per Share
Marketwire - Fri Aug 09, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a notice to BELLUS Health indicating that Thallion has negotiated a final and binding agreement with Iberville Development Leasing Limited pursuant to which the latter has agreed to fully, finally and irrevocably release Thallion from its obligations under the lease dated December 2, 2010, in exchange for the payment of an amount which is less than the provision for the termination of such lease included in the minimum net cash component announced on August 2, 2013. The cash component of the consideration payable on the effectiveness of the Arrangement has been increased by $0.0124 per common share resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being $0.1889 per common share.
Thallion Announces Shareholder Approval for Plan of Arrangement and Date and Time for the Motion for Final Court Order
Marketwire - Tue Aug 06, 4:00PM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that the shareholders of Thallion approved the previously announced plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health at the annual and special meeting of the shareholders held today in Montreal (the "Meeting"). Pursuant to the Arrangement, the Shareholders will receive cash consideration of at least $0.1765 per common share, and one contingent value right ("CVR") per common share, entitling the holder thereof to: (A) its pro rata share of 100% of any additional purchase price consideration to be received from Premium Brands Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), (B) its pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS Health, capped at $6.5 million (or $0.1812 per CVR), and Copyright its pro rata share of 100% of any net proceeds generated from the licensing, selling or otherwise commercializing of (i) diagnostic products or services using certain Caprion Proteomics Inc. products, and (ii) all issued patents or pending patents pertaining to such Caprion Proteomics Inc. products, in respect of which Thallion has an ownership interest or monetary entitlement.
RETRANSMISSION/Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 9:54AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component").
Thallion Pharmaceuticals Announces Minimum Effective Net Cash of $7,500,000 Resulting in Cash Component of at Least $0.1765 Per Share
Marketwire - Fri Aug 02, 7:01AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) and BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") announced today that in accordance with the acquisition agreement dated June 17, 2013, as amended (the "Acquisition Agreement") pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health, the Effective Net Cash (within the meaning of the Acquisition Agreement) is equal to a minimum of $7,500,000 including the deemed proceeds for the exercise or cancellation and treatment as per the plan of Arrangement of "in-the-money" options of approximately $500,000, resulting in the cash component of the consideration to be received by Thallion's shareholders on the effectiveness of the Arrangement being at least $0.1765 per common share (the "Minimum Cash Component").
Thallion Announces 2013 Second Quarter Operating Results
Marketwire - Thu Jul 25, 4:01PM CDT
Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) today announced its operational and financial results for the 2013 second quarter ended May 31, 2013.
RETRANSMISSION: BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Fri Jul 12, 4:25PM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") and Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment") to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health.
BELLUS Health Amends Terms of CVRs in Connection With Its Acquisition of Thallion
Marketwire - Wed Jul 10, 6:01AM CDT
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health") and Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE: TLN) announced today that they have entered into an amendment (the "Amendment") to the acquisition agreement dated June 17, 2013 pertaining to the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health.
Thallion's Annual and Special Meeting to Be Held August 6, 2013
Marketwire - Tue Jul 02, 2:10PM CDT
Thallion Pharmaceuticals Inc. (TSX VENTURE: TLN) ("Thallion") announced today that the Superior Court of Quebec has issued an interim order authorizing Thallion to hold an annual and special meeting of the shareholders of Thallion, at which shareholders will be asked to approve the proposed plan of arrangement (the "Arrangement") involving the acquisition of Thallion by BELLUS Health Inc. ("BELLUS Health") (TSX: BLU), which was announced previously on June 18, 2013.
Jaguar Recommends Disclosure of Net Cash Calculation
Filing Services Canada - Wed Jun 26, 2:20PM CDT
Jaguar Financial Corporation,("Jaguar") (TSX: JFC) today recommended that Thallion Pharmaceuticals Inc. ("Thallion" or the "Company") disclose the May 31, 2013 Net Cash calculation which was omitted in the Acquisition Agreement with BELLUS Health Inc. ("BELLUS") filed on SEDAR.
Thallion Reaffirms Support of BELLUS Health Acquisition
Marketwire Canada - Thu Jun 20, 6:30AM CDT
Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE:TLN) announced today that, in response to the press release dated June 18, 2013 issued by Jaguar Financial Corporation ("Jaguar"), it reaffirms its support of the BELLUS Health Inc. ("BELLUS") (TSX:BLU) proposed transaction outlined in Thallion's and BELLUS' joint press release dated June 18, 2013.
